SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for Greater Cannabis Company, Inc. (GCAN) (CIK 0001695473) (TRFA) — Jan 27, 2020

Greater Cannabis Company, Inc. (GCAN) (CIK 0001695473)
Date: Jan. 27, 2020 · CIK: 0001695473 · Accession: 0000000000-20-000683

AI Filing Summary & Sentiment

File numbers found in text: 333-235938

Date
January 27, 2020
Author
Not clearly detected
Form
UPLOAD
Company
Greater Cannabis Company, Inc. (GCAN) (CIK 0001695473)

Letter

January 27, 2020 Aitan Zacharin Chief Executive Officer The Greater Cannabis Company, Inc. 15 Walker Avenue, Suite 101 Baltimore, MD 21208 Re:The Greater Cannabis Company, Inc. Registration Statement on Form S-1 Filed January 16, 2020 File No. 333-235938 Dear Mr. Zacharin: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at 202-551-3798 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Dale S. Bergman, Esq.

Show Raw Text
January 27, 2020
Aitan Zacharin
Chief Executive Officer
The Greater Cannabis Company, Inc.
15 Walker Avenue, Suite 101
Baltimore, MD 21208
Re:The Greater Cannabis Company, Inc.
Registration Statement on Form S-1
Filed January 16, 2020
File No. 333-235938
Dear Mr. Zacharin:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Ada D. Sarmento at 202-551-3798 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Dale S. Bergman, Esq.